mAbxience and HP Drive the Use of Artificial Intelligence in Biomanufacturing and Biosimilar Development
mAbxience, a Fresenius entity, and HP Inc. have launched a joint project to develop an AI solution for optimizing the production of monoclonal antibodies and biosimilars.
The project involves creating a digital twin of the biological process to enhance predictability, consistency, and efficiency in large-scale biomanufacturing.
The AI tool uses real production data processed through advanced neural network models and has been validated in an industrial setting.
The solution allows simulation, analysis, and optimization of cell culture manufacturing stages, aiming to increase yields and reduce process variability.
This initiative is the first under a strategic collaboration framework between HP and mAbxience, with plans to apply AI across multiple operational areas globally.
The prototype was developed and validated at mAbxience's facility in León, Spain, and has potential for replication across other sites and processes worldwide.
The collaboration aims to strengthen mAbxience's position as a cost-competitive biomanufacturing partner and improve patient access to high-quality biologic medicines.